Project Grant R00HL170075
Award Date
7/21/25
Completion Date
6/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Newark, NJ 07107, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $486,291 to Rutgers, The State University of New Jersey, Camden Division to develop nucleic acid nanoparticle (NANP) technology for efficiently delivering the CRISPR/Cas9 genome editing system into hematopoietic stem cells (HSCs). The goal is to enhance the targeting precision and efficacy of gene editing in HSCs to revolutionize the treatment of genetic blood...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $248,955 to Howard University from March 1, 2025 to February 29, 2028. The grant supports research to characterize the roles of bivalent chromatin domains in regulating cellular plasticity during CD4+ T cell differentiation. Key objectives include: 1) identifying plasticity-related bivalent domains that dynamically change during T cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $131,211 to The Leland Stanford Junior University to conduct research on "High-Resolution Tracking of T Cell Differentiation to Predict and Control Alloreactive Disease" related to allogeneic hematopoietic stem cell transplantation. The overarching goal is to use high-resolution sequencing techniques to identify and track alloreactive T cells in order to...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512 to generate a comprehensive single-cell transcriptomic and epigenomic map of human bone marrow cells and experimentally establish the mesenchymal hierarchy in human bone. The primary goals are to unravel the complex cellular signaling networks in bone marrow and provide insights into how cell fates are regulated, with the long-term aim of developing novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $792,498 to the Trustees of Indiana University, Indianapolis (IU Indianapolis) to conduct research on hematopoietic stem cells (HSCs) and their regulation under low oxygen tension (hypoxia). The primary goals are to: 1) understand how hypoxia activates the transcription factor TFE3 to facilitate HSC self-renewal, 2) determine...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $560,828 to Yale University to conduct research on the role of linker histones in regulating the lymphoid differentiation potential of hematopoietic stem and progenitor cells. The research aims to define the molecular pathway by which specific linker histone isoforms or abundance influence the lineage output of multipotent...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 - Cardiovascular Diseases Research, is providing $445,000.00 to The Children's Hospital of Philadelphia (CHOP) over the period of July 15, 2025 to June 30, 2028. The funding supports research to determine the molecular mechanisms by which the Tropomyosin 1 gene product regulates the TNF-alpha signaling pathway in hematopoietic stem and progenitor cells and their hemogenic endothelial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $623,874 to uncover novel regulatory pathways and functions of the telomerase RNA component (TERC) in the hematopoietic system. The research aims to identify regulators of TERC decay and its direct functions outside of telomere length regulation, which could explain the disproportionate role of TERC mutations in bone marrow failure. The...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...